Highly Active Antiretroviral Therapy Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions: HIV Infections; Fatty Liver Disease Interventions: Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day; Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day; Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor: Fundacion SEIMC-GESIDA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions: HIV Infections; Fatty Liver Disease Interventions: Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day; Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day; Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor: Fundacion SEIMC-GESIDA Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions: HIV Infections; Fatty Liver Disease Interventions: Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day; Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day; Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor: Fundacion SEIMC-GESIDA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
Conditions: HIV Infections; Fatty Liver Disease Interventions: Drug: Dolutegravir (DTG) 50 mg/day + Rilpivirine (RPV) 25mg per day; Drug: Tenofovir disoproxil fumarate (TDF) 245 mg per day or Tenofovir alafenamide (TAF) 25 mg per day + Emtricitabine (FTC) 200 mg per day + Rilpivirine 25 mg per day; Drug: Continue with their previous treatment. Any pre vious HAART that does not contain Rilpivirine. Sponsor: Fundacion SEIMC-GESIDA Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2023 Category: Research Source Type: clinical trials
Nursing Counseling to the Change of Behavior of Alcohol Consumption in Patients in HAART
Conditions: HIV; Alcohol Drinking Interventions: Behavioral: Nursing Counseling in the change of Alcohol Consumption Behavior in patients receiving HAART; Behavioral: Habitual Counseling Sponsors: Universidad Peruana Cayetano Heredia; John E. Fogarty International Center (FIC); CARIBBEAN, CENTRAL AND SOUTH AMERICA NETWORK FOR HIV EPIDEMIOLOGY Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 13, 2019 Category: Research Source Type: clinical trials